Point of care DNA diagnostics: faster, better, cheaper

Photo of Dr. Chris Harder

Dr. Chris Harder

Vice President of Diagnostics, Spartan Bioscience

Monday September 22, 2014 12:00 - 13:00

Mackenzie Building Room 3356, Carleton University

 

 

abstract

Point of care or home use diagnostic tests are becoming more and more common. Imagine the day when you can have a Strep throat test right in the Dr's office or get screened before getting on a plane for flu. This future is getting closer and closer. Spartan Bioscience commercializes point of care DNA testing systems and hopes to make the above a reality in the not too distant future. I'll present some of the insights and challenges with product development in a new space and how technology, regulation and marketing work together to bring a diagnostic test to market

biography

Dr. Chris Harder is the VP of Diagnostics at Spartan Bioscience. Dr. Harder joined Spartan in 2006. As one of Spartan's first employees, Chris assembled the R&D team and invented many of the company's core technologies. Dr. Harder oversees the development of new diagnostic tests, reagent manufacturing, clinical affairs and regulatory affairs. Dr. Harder was the project manager on Spartan's first FDA 510(k) cleared test. Dr. Harder holds a bachelor's degree in biochemistry from the University of Ottawa, and a Ph.D. in biochemistry from the University of Ottawa.

Last updated September 12, 2014